Seino M, Abe K, Irokawa N, Ito T, Yasujima M, Sakurai Y, Chiba S, Saito K, Ritz K, Kusaka T, Miyazaki S, Yoshinaga K
Tohoku J Exp Med. 1978 Mar;124(3):197-203. doi: 10.1620/tjem.124.197.
The effect of furosemide on urinary kallikrein excretion was studied in 10 patients with essential hypertension and 9 normal volunteer subjects. After intravenous administration of furosemide and 2 hours of upright posture, urine volume (UV), urinary sodium (UNaV) and potassium (UKV) excretion, plasma renin activity (PRA), plasma aldosterone concentration (PAC) and urinary kallikrein markedly increased. However, the augmentation of urinary kallikrein in patients with essential hypertension (1.50 +/- 0.19 EU/2 hr) was less remarkable than that in normal subjects (2.33 +/- 0.24 EU/2 hr), although the same degrees of response were observed in PRA and PAC. The increments of UV, UNaV and UKV in patients with essential hypertension were also significantly lower than in normal subjects. Significant positive relations were found between urinary kallikrein and UV or UNaV in both hypertensive and normotensive groups, but there was no such correlation before fursemide administration. It is likely that diuresis and natriuresis induced by furosemide are somehow associated with an increase in urinary kallikrein excretion. Blunted response of urinary kallikrein in essential hypertension may suggest an abnormality in the renal kallikrein-kinin system in this disease.
在10例原发性高血压患者和9名正常志愿者中研究了速尿对尿激肽释放酶排泄的影响。静脉注射速尿并保持2小时直立姿势后,尿量(UV)、尿钠(UNaV)和钾(UKV)排泄、血浆肾素活性(PRA)、血浆醛固酮浓度(PAC)和尿激肽释放酶均显著增加。然而,原发性高血压患者尿激肽释放酶的增加量(1.50±0.19 EU/2小时)不如正常受试者(2.33±0.24 EU/2小时)显著,尽管在PRA和PAC方面观察到相同程度的反应。原发性高血压患者的UV、UNaV和UKV增加量也显著低于正常受试者。在高血压组和正常血压组中,尿激肽释放酶与UV或UNaV之间均存在显著的正相关,但在使用速尿前不存在这种相关性。速尿诱导的利尿和利钠作用可能在某种程度上与尿激肽释放酶排泄增加有关。原发性高血压患者尿激肽释放酶反应减弱可能提示该疾病肾激肽释放酶-激肽系统存在异常。